Date: November 02, 2026
Board Meeting Outcomes
This disclosure serves as a material update regarding IGL Spirits Limited (IGSL) in connection with the Scheme of Arrangement among India Glycols Limited (Demerged Company), Ennature Bio Pharma Limited (Resulting Company 1), and IGL Spirits Limited (Resulting Company 2).
The disclosure is made pursuant to:
- Observation letter no. NSE/LIST/48932 dated 17th November, 2025 from National Stock Exchange of India Limited
- Observation letter no. DCS/AMAL/TS/R37/3905/2025-26 dated 19th November, 2025 from BSE Limited
- SEBI Master Circular No. HO/491l 411 4(7)2025-CFD-POD21l 13762/2026 dated 30th January, 2026 (as amended)
Other Operational / Legal / Strategic Disclosures
IGL Spirits Limited has received Listing and Trading Approvals from both BSE Limited and National Stock Exchange of India Limited on November 02, 2026, for the equity shares issued and allotted pursuant to the Scheme of Arrangement.
Approval Details:
- Stock Exchanges: BSE Limited and National Stock Exchange of India Limited
- Type of Approval: Listing and Trading Approval
- Security Type: Equity Shares
- Number of Shares Listed: 6,70,26,765 Equity shares of ₹5 each
- Date of Approval: November 02, 2026
- Date of Commencement of Trading: November 04, 2026
The Scheme of Arrangement was implemented under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013.
Copy of the Listing and Trading Approval letters are available on the websites of BSE and NSE at:
- BSE: https://www.bseindia.com/markets/marketinfo/noticescirculars?id=0
- NSE: https://www.nseindia.com/resources/exchange-communication-circulars
KMP / Board / Auditor Changes
Not Specified
Dividend Declaration or Non-Declaration
Not Specified
Financial Results (Standalone & Consolidated)
Not Specified
Disinvestment / Strategic Actions
Not Specified